CareLit Fachartikel

T Safety And Performance In Respimat® (TIOSPIR™): Safety And Efficacy In Patients With T HH® Use At Baseline

R Koczulla, P Calverley, A Anzueto, R Dahl, A Müller, A Fowler, N Metzdorf, R Wise, D Dusser · Pneumologie · 2016 · Heft 02

Dokument
1176356
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
R Koczulla, P Calverley, A Anzueto, R Dahl, A Müller, A Fowler, N Metzdorf, R Wise, D Dusser
Ausgabe
Heft 02 / 2016
Seiten
–
Erschienen: 2016-02-09 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0036-1572049

Zusammenfassung

Rationale: The TIOSPIR™ trial showed that tiotropium (T) Respimat® (Resp) 5 µg and HandiHaler® (HH) 18 µg have similar safety and exacerbation (exa) efficacy profiles in patients (pts) with COPD. We present results for all pts using T HH® at baseline. Methods: TIOSPIR™ (n = 17,135) compared safety and efficacy of once-daily T Resp 5 and 2.5 µg with once-daily HH 18 µg in pts with COPD. Primary endpoints were time to death and time to first COPD exa. Safety, incl. cardiovascular (CV) safety, was assessed. Pts receiving T at baseline from countries where T Resp was unavailable at the time of study initiation (base…

Schlagworte

Baseline Safety Similar Tiospir Treated Groups Versus Fatal Efficacy Death Respimat Patients Pneumologie